Abstract: The invention concerns methods for detecting exposure to a RIP II family toxin in a biological sample. The method is based on identifying the enzymatic activity of the toxin on 28sRNA and employs sensitive and specific amplification steps that allow detection in clinical samples.
Type:
Grant
Filed:
May 9, 2018
Date of Patent:
March 16, 2021
Assignee:
THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)
Abstract: An isolated monoclonal antibody or antigen-binding fragment thereof binds to F. tularensis lipopolysaccharide (Ft LPS). The antibody preferably lacks an Fc region or has an impaired Fc-region. The antibody may be formulated into a pharmaceutical composition along with a pharmaceutically acceptable carrier, excipient or diluent. It may be provided in a kit with means for detection of the antibody and instructions for use. A therapeutically effective amount of such an antibody can be used for prophylaxis, treatment or amelioration of Ft infection and for inhibiting Ft uptake by cells in a subject. The antibody can also be used to detect Ft infection. Also disclosed is an isolated nucleic acid molecule encoding the antibody, an expression vector having the isolated nucleic acid molecule, and a host cell transfected with such an expression vector.
Type:
Grant
Filed:
July 3, 2019
Date of Patent:
January 5, 2021
Assignee:
THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)
Abstract: An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to ricin toxin, an expression vector including the isolated nucleic acid molecule and a host cell transfected with said isolated nucleic acid molecule or with the expression vector, a pharmaceutical composition including as an active ingredient the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule or the immunoconjugate and a pharmaceutically acceptable carrier, excipient or diluent, and a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule, the immunoconjugate or the pharmaceutical composition.
Type:
Grant
Filed:
November 25, 2015
Date of Patent:
March 19, 2019
Assignee:
THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)
Inventors:
Ohad Mazor, Ronit Rosenfeld, Arie Ordentlich, Tal Noy-Porat
Abstract: The invention provides a pharmaceutical composition comprising as an active ingredient a combination of three isolated monoclonal antibodies or any antigen-binding fragment thereof which bind ricin toxin and neutralize its toxic effects, and a pharmaceutically acceptable carrier, excipient or diluent. The invention also provides a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition.
Type:
Grant
Filed:
January 4, 2017
Date of Patent:
February 19, 2019
Assignee:
THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)
Inventors:
Ohad Mazor, Ronit Rosenfeld, Arie Ordentlich, Tal Noy-Porat
Abstract: Fusion polypeptides are provided including modified human Acetylcholinesterase conjugated to the Fc region of an immunoglobulin. Methods of preparing these polypeptide constructs and uses thereof as scavenging agents of organophosphate compounds are described.
Type:
Grant
Filed:
April 4, 2016
Date of Patent:
October 23, 2018
Assignee:
THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)
Abstract: This disclosure generally relates to therapeutic antibodies for treating Bacillus anthracis (B. anthracis) infection, to specific variants thereof, pharmaceutical composition comprising them and to methods for their use.
Type:
Grant
Filed:
July 30, 2015
Date of Patent:
August 15, 2017
Assignee:
THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)